MyUTI is a precision medicine company focused on addressing the significant health issue of Urinary Tract Infections (UTIs), which affect 80% of women in the U.S. Their innovative at-home UTI test provides accurate results within 24 hours and offers remote treatment options through telehealth partners, reducing hospital visits and associated costs. Currently, MyUTI is raising a $750,000 Series Seed round at a $4 million valuation cap with a 20% discount, of which $420,000 has already been secured. The funds will be used to scale operations, increase telehealth partnerships, and unlock a $250,000 grant, with goals to grow the customer base and increase revenue from $145,000 to $1 million by 2025. MyUTI's go-to-market strategy includes partnerships with health systems and major retailers like CVS and Target, as well as telehealth partners, to expand its consumer and insurance-reimbursable services.
Join Rockies Venture Club for the MyUTI Investor Update to learn more about the companies progress, meet the executive team, discuss the opportunity alongside existing RVC investors, and officially announce the deal in play. The Investor Update will take place virtually and will cover all the major due diligence questions such as IP, competition, leadership, funding strategy, exit strategy, use of funds, milestones, etc.
The format for the Investor Update will be as follows:
Want to learn more? Please visit our main website: